Small molecule inhibitor against onco-mucins disrupts Src/FosL1 axis to enhance gemcitabine efficacy in pancreatic ductal adenocarcinoma.
Zhang C, Atri P, Nallasamy P, Parte S, Rauth S, Nimmakayala RK, Marimuthu S, Chirravuri-Venkata R, Bhatia R, Halder S, Shah A, Cox JL, Smith L, Kumar S, Foster JM, Kukreja RC, Seshacharyulu P, Ponnusamy MP, Batra SK.
Zhang C, et al. Among authors: cox jl.
Cancer Lett. 2022 Dec 28;551:215922. doi: 10.1016/j.canlet.2022.215922. Epub 2022 Sep 19.
Cancer Lett. 2022.
PMID: 36285687
Free PMC article.